Drug Discovery World

MARCH 5, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Virus 147

Virus Vaccine Research Disease 147

Drug Discovery World

MAY 13, 2024

Reece Armstrong speaks to Melanie Adams-Cioaba , Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.”

Vaccine 147

Vaccine Virus Small Molecule Disease 147

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Drug Discovery World

JUNE 10, 2024

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna Covid-19 vaccines.

Vaccine 147

Vaccine FDA Approval FDA Virus 147

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

MARCH 13, 2024

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The researchers found that both vaccines generated neutralising antibodies against the most recent strain of Omicron, BA.2.86. strains after their booster vaccination.

Vaccine 130

Vaccine Research Virus Hospitals 130

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.

Vaccine 130

Vaccine Trials Animal Testing Virus 130

Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” .

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

AUGUST 15, 2023

Viruses have different proteins on their surfaces that are often the targets of therapeutics like monoclonal antibodies and vaccines. Ideally, new antivirals won’t be specific to one virus or protein, so they will be ready to treat new viruses that emerge without delay and will be able to overcome the development of resistance. “We

Virus 130

Virus Vaccine Treatment Research 130

Drug Discovery World

SEPTEMBER 15, 2023

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. A next-generation rabies vaccine with improved immunogenicity and simpler manufacturing represents an opportunity to establish wider accessibility to rabies prevention worldwide.

Vaccine 130

Vaccine Trials Immune Response Virus 130

Drug Discovery World

AUGUST 7, 2023

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘ Disease X ‘, a term used because what might trigger the next pandemic is unknown.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

FEBRUARY 14, 2024

Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason) , Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. This would give more people much faster access to more effective vaccines.

Vaccine 147

Vaccine Production Virus DNA 147

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). The post Study suggests ways to improve future HIV vaccine candidates appeared first on Drug Discovery World (DDW).

Vaccine 147

Vaccine Clinical Trials Laboratories Virus 147

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

AUGUST 23, 2023

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.”

FDA Approval 130

FDA Approval Vaccine FDA Virus 130

Drug Discovery World

MARCH 15, 2024

Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. The company’s vaccine for Chikungunya virus (IXCHIQ) was approved by the US Food and Drug Administration (FDA) in November 2023 and is the world’s first and only vaccine for Chikungunya.

Vaccine 147

Vaccine Science Clinical Trials Virus 147

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

AUGUST 9, 2023

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect infants and toddlers from RSV.

Vaccine 130

Vaccine Virus Disease Drugs 130

Drug Discovery World

MARCH 24, 2023

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

Vaccine 130

Vaccine Virus Disease Drugs 130

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Clamp technology . The University of Queensland. .

Vaccine 130

Vaccine Immune Response Virus Engineering 130

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccine 130

Vaccine Immune Response Virus Disease 130

Drug Discovery World

AUGUST 19, 2024

Viruses of the family Flaviviridae, including Japanese encephalitis virus (JEV), Dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), and Tick-borne encephalitis virus, are known to cause severe diseases. Not only Dengue virus but also JEV and ZIKV have no medication for treatment.”

Treatment 147

Treatment Virus Vaccine Disease 147

Drug Discovery World

DECEMBER 22, 2022

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130

Virus Clinical Trials Drugs Hospitals 130

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccine 130

Vaccine Trials Clinical Trials Virus 130

Drug Discovery World

MARCH 17, 2023

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. HDV infection is rare, but the effects of chronic HDV infection are potentially extremely serious.

Virus 130

Virus Regulations Licensing Licensing 130

SCIENMAG: Medicine & Health

DECEMBER 21, 2023

Researchers have identified a previously unrecognized class of antibodies—immune system proteins that protect against disease—that appear capable of neutralizing multiple forms of flu virus.

Virus 77

Virus Vaccine Disease Research 77

Drug Discovery World

OCTOBER 31, 2022

A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems. . The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 5 predominance for immunocompromised adults. .

Vaccine 130

Vaccine Virus Hospitals Treatment 130

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Sugars, such as sucrose are common stabilizers in many vaccines.

Vaccine 79

Vaccine Immune Response Clinical Trials Virus 79

Chemical Biology and Drug Design

NOVEMBER 13, 2023

Challenges involved in vaccines formulation were also featured. Use of computational methods and models for vaccine development has revolutionized the traditional methods of vaccine development. Main role of mRNA vaccines in the COVID-19 challenge was discussed.

Vaccine 100

Vaccine Laboratories RNA Virus 100

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

Drug Discovery World

JULY 12, 2024

Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. for disease-modifying Parkinson’s treatment Mission Therapeutics has been awarded $5.2

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

Drug Discovery World

SEPTEMBER 26, 2024

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases.

Virus 130

Virus Therapies Vaccine Treatment 130

Drug Discovery World

DECEMBER 15, 2023

The Oxford Vaccine Group (OVG), which led the development of the Oxford vaccine for Covid-19, has been awarded a total of £7.8 ($9.8) million by UK Aid for research into the prevention of five diseases with epidemic or pandemic potential.

Vaccine 147

Vaccine Virus Science Disease 147

Drugs.com

SEPTEMBER 7, 2023

7, 2023 -- While it doesn't prevent infection altogether, new research shows the mpox vaccine does reduces the severity of disease in those who fall ill from the virus. THURSDAY, Sept. An international team of scientists found that those people who.

Vaccine 85

Vaccine Virus International Disease 85